What is BioLineRx?
BioLineRx is a specialized biopharmaceutical organization dedicated to the advancement of innovative therapies targeting oncology and rare diseases. Headquartered in Israel with a robust U.S. operational footprint, the company bridges the gap between early-stage scientific discovery and late-stage clinical development. Its diverse pipeline includes investigational treatments for multiple myeloma, sickle cell disease, and various solid tumors, including pancreatic cancer. By integrating end-to-end development capabilities with strategic commercialization planning, BioLineRx aims to address significant unmet medical needs, positioning itself as a critical player in the global life sciences sector.
How much funding has BioLineRx raised?
BioLineRx has raised a total of $125M across 4 funding rounds:
Stock Offering
$50M
Debt
$40M
Other Financing Round
$15M
Debt
$20M
Stock Issuance/Offering (2007): $50M, investors not publicly disclosed
Debt (2022): $40M led by Kreos Capital Group
Other Financing Round (2023): $15M, investors not publicly disclosed
Debt (2024): $20M featuring Kreos Capital Group and BlackRock
Key Investors in BioLineRx
Kreos Capital Group
Kreos Capital Group is a London-based firm specializing in growth debt and investment services, providing essential capital to high-growth companies since 1998.
BlackRock
BlackRock is a premier global investment management firm that provides institutional clients with comprehensive risk management, advisory services, and diverse asset class exposure.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for BioLineRx?
With the recent infusion of capital, BioLineRx is expected to prioritize the advancement of its lead clinical programs. The strategic focus will likely center on accelerating patient enrollment for ongoing trials and strengthening its commercial infrastructure to support future product launches. As the company navigates the complexities of regulatory approval and market entry, this financing provides the necessary runway to sustain its research momentum. Investors will be closely monitoring the firm's ability to translate its scientific milestones into tangible clinical outcomes, which will be pivotal for long-term value creation in the biopharmaceutical market.
See full BioLineRx company page
